The Opioid Crisis and the Future of Addiction and Pain Therapeutics.

The Opioid Crisis and the Future of Addiction and Pain Therapeutics.

Publication date: Sep 03, 2019

Opioid misuse and addiction are a public health crisis resulting in debilitation, deaths, and significant social and economic impact. Curbing this crisis requires collaboration among academic, government, and industrial partners towards the development of effective non-addictive pain medications, interventions for opioid overdose, and addiction treatments. A two-day meeting, The Opioid Crisis and the Future of Addiction and Pain Therapeutics: Opportunities, Tools, and Technologies Symposium, was held at the National Institutes of Health to address these concerns and to chart a collaborative path forward. The meeting was supported by the NIH HEAL (Helping to End Addiction Long-term) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid crisis. The event was unique in bringing together two research disciplines, addiction and pain, to create a forum for cross-communication and collaboration. The output from the symposium will be considered by the HEAL Initiative; this article summarizes the scientific presentations and key takeaways. Improved understanding of the etiology of acute and chronic pain will enable the discovery of novel targets and regulatable pain circuits for safe and effective therapeutics, as well as relevant biomarkers to ensure adequate testing in clinical trials. Applications of improved technologies including reagents, assays, model systems, and validated probe compounds will likely increase the delivery of testable hypotheses and therapeutics to enable better health outcomes for patients. The symposium goals were achieved by increasing interdisciplinary collaboration to accelerate solutions for this pressing public health challenge and provide a framework for focused efforts within the research community. SIGNIFICANCE STATEMENT: This article summarizes key messages and discussions resulting from a two-day symposium focused on challenges and opportunities in developing addiction- and pain-related medications. Speakers and attendees came from 40 US states and 15 countries bringing perspectives from academia, industry, government, and healthcare by researchers, clinicians, regulatory experts, and patient advocates.

Coussens, N.P., Sittampalam, G.S., Jonson, S.G., Hall, M.D., Gorby, H.E., Tamiz, A.P., McManus, O.B., Felder, C.C., and Rasmussen, K. The Opioid Crisis and the Future of Addiction and Pain Therapeutics. 03982. 2019 J Pharmacol Exp Ther.

Concepts Keywords
Addiction Reagents assays systems
Biomarkers Pain
Chronic Pain Acute chronic pain
Clinical Trials Drug targeting
Cross Sackler family
Etiology Psychiatry
Healthcare Substance dependence
Interdisciplinary Addiction
NIH Health
Opioid Neuroscience
Opioid Overdose
Pain
Pain Medications
Patient Advocates

Semantics

Type Source Name
disease MESH drug tolerance
disease MESH community
drug DRUGBANK Tropicamide
disease MESH chronic pain
gene UNIPROT ENG
gene UNIPROT ARID1A
disease MESH development
gene UNIPROT IMPACT

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *